

(19) World Intellectual Property
Organization
International Bureau



24 JUN 2005



(43) International Publication Date
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number
WO 2004/060374 A1

(51) International Patent Classification⁷: **A61K 31/496**,
31/381, 31/343, 31/15, 31/4525, 31/135, A61P 25/24

(21) International Application Number:
PCT/JP2003/016724

(22) International Filing Date:
25 December 2003 (25.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
NO. 2002-379003
60/470,481
27 December 2002 (27.12.2002) JP
14 May 2003 (14.05.2003) US

(71) Applicant (for all designated States except US): **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP];
9, Kanda-Tsukasacho 2-chome, Chiyoda-ku, Tokyo
101-8535 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KIKUCHI, Tetsuro**
[JP/JP]; 157-13, Kawauchicho Komatsunishi, Tokushima-

shi, Tokushima 771-0104 (JP). **IWAMOTO, Taro** [JP/US];
36, Boundinot Street, Princeton, NJ 08540 (US). **HIROSE,**
Tsuyoshi [JP/JP]; 8-9-502, Sakoichibancho, Tokushima-
shi, Tokushima 770-0021 (JP).


(74) Agents: **ASAMURA, Kiyoshi** et al.; Room 331, New
Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku,
Tokyo 100-0004 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS



(57) Abstract: The pharmaceutical composition of the present invention comprises (1) a carbostyryl derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyryl derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.

WO 2004/060374 A1



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

DESCRIPTION

CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE
INHIBITORS FOR TREATMENT OF MOOD DISORDERS

TECHNICAL FIELD

The present invention provides pharmaceutical compositions comprising carbostyryl derivatives that act as dopamine-serotonin system stabilizers in
5 combination with serotonin reuptake inhibitors in a pharmaceutically acceptable carrier. Further, the present invention provides methods of using the compositions of the present invention to treat mood disorders such as depression and major depressive
10 disorder.

BACKGROUND ART

The number of people with mood disorders such as major depressive disorder, and exhibiting various symptoms of depressions is increasing every year for
15 numerous reasons such as social stress, unemployment, disease, and poverty. Depression is a major social problem throughout the world. For example, in Japan the occurrence rate of depression in the generation older than 65 years is 5% or more, including major
20 depressive disorder. Some of the depression in this population is associated with mental disturbances representing senile diseases associated with dementia

and neurosis. Many depressed patients show high recurrence rate, and severe depressive symptoms are major causes of suicide and drug abuse (Nishimura Ken, "NIPPON RONEN IGAKUZASSHI", Vol. 33, pp 503-504
5 (1996)).

Since the period of 1950, tricyclic antidepressant drugs (e.g., imipramine, desipramine, amitriptyline, etc.) have been developed that act to inhibit monoamine reuptake. They are frequently used
10 for treating patients suffering from mood disorders, such as depression and major depressive disorder. However, these drugs have side-effects such as the following: dry mouth, hazy eyes, dysuria, constipation, recognition disturbance and the like due to
15 anticholinergic activity; cardiovascular side-effects such as, orthostatic hypotension, tachycardia and the like on the basis of α_1 -adrenoreceptor antagonist activity; side-effects such as, sedation, increase in the body weight and the like on the basis of histamine-
20 H_1 receptor antagonist activity.

Since 1980, serotonin reuptake inhibitors have been developed, including but not limited to fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, escitalopram, fluvoxamine, paroxetine and
25 sertraline, and these inhibitors have side-effects such as recognition disturbance, sleep disturbance, and exacerbation of anxiety and agitation. Additionally, these inhibitors also have other side effects in the

digestive organs, such as nausea, vomiting and the like.

For the reason that the mood disorders such as depressive symptoms, depression and the like are
5 diseases with severely strong psychalgia, the manifestation of new symptoms on the basis of these side-effects are quite serious problems in the therapy of mood disorders (Shioe Kunihiro, Kariya Tetsuhiko, "SHINKEI SEISHIN YAKURI", Vol. 11, pp 37-48 (1989);
10 Yamada Mitsuhiko, Ueshima Kunitoshi, "RINSHOU SEISHIN YAKURI", Vol. 1, pp 355-363 (1998)).

Although the mood disorders including depression and major depressive disorder are heterogeneous diseases, and the causes of these
15 diseases are not been fully understood, it is likely that the abnormalities of monoaminergic central nervous system caused by serotonin, norepinephrine and dopamine and the like, and the abnormality of various hormones and peptides as well as various stressors are causes of
20 depression and various mood disorders (Kubota Masaharu et al., "RINSHOU SEISHIN IGAKU", Vol. 29, pp 891-899 (2000)). For these reasons, even though antidepressant drugs, such as tricyclic antidepressants and serotonin reuptake inhibitors were used, these drugs are not
25 always effective in treating all depressed patients. About 30% of the depressed patients do not respond to the primarily selected antidepressants (Nelson, J. C, et al., J. Clin. Psychiatry, 55, pp 12-19 (1994)).

Further, when a second or third antidepressant is administered to these patients, insufficient improvements of the symptoms occurs in about 10% of these patients (Inoue Takeshi, Koyama Tsukasa, "RINSHOU SEISHIN IGAKU", Vol. 38, pp 868-870 (1996)). These patients are called as refractory depression patients.

In some cases, electric shock therapy is used to treat refractory depression, and the efficacy of this treatment has been reported. However, in fact, the condition of numerous patients is not improved (Inoue Takeshi, Koyama Tsukasa, "RINSHOU SEISHIN YAKURI", Vol. 2, pp 979-984 (1999)). Additionally, psychological anguish experienced by these patients and their families concerning the use of the electric shock therapy can be severe.

New therapeutic trials involve proposed combined therapies using an atypical antipsychotic drug, such as olanzapine, which is an agent for treating for schizophrenia (antipsychotic drug), together with an antidepressant drug such as serotonin reuptake inhibitor (EP 0 367 141, WO 98/11897, WO99/61027, WO99/62522, U.S. 2002/0123490A1 and the like). However, commercially available atypical antipsychotic drugs have significant problems relating to their safety. For example, clozapine, olanzapine and quetiapine increase body weight and enhance the risk of diabetes mellitus (Newcomer, J. W. (Supervised Translated by Aoba Anri), "RINSHOU SEISHIN YAKURI",

Vol. 5, pp 911-925 (2002); Haupt, D. W. and Newcomer, J. W (Translated by Fuji Yasuo and Misawa Fuminari), "RINSHOU SEISHIN YAKURI", Vol. 5, pp 1063-1082 (2002)). In fact, urgent safety alerts have been issued in Japan relating to hyperglycemia, diabetic ketoacidosis and diabetic coma caused by olanzapine and quetiapine, indicating that these drugs were subjected to dosage contraindication to the patients with diabetes mellitus and patients having anamnesis of diabetes mellitus.

10 Risperidone causes increases serum prolactin levels and produces extrapyramidal side effects at high dosages. Ziprasidone enhances the risk of severe arrhythmia on the basis of cardio-QTc prolongation action. Further, clozapine induces agranulocytosis, so that clinical use thereof is strictly restricted (van Kammen, D. P. (Compiled under Supervision by Murasaki Mitsuroh), "RINSHOU SEISHIN YAKURI", Vol. 4, pp 483-492 (2001)).

15

Accordingly what is needed are new compositions useful for treating mood disorders, particularly, depression and major depressive disorder, which are efficacious and do not cause the deleterious side effects associated with prior art compounds.

20

DISCLOSURE OF THE INVENTION

The present invention solves the problem described above by providing novel compositions and methods of using these compositions for treating mood disorders, particularly depression and major depressive

25

disorder.

The present invention provides solutions to the above-mentioned problems, and demonstrates that the mood disorders such as depression, major depressive and the like can be treated effectively by administering to a patient with such disorder a pharmaceutical composition comprising at least one carbostyryl derivative that is a dopamine-serotonin system stabilizer in combination with at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier.

A preferred carbostyryl derivative of the present invention that is a dopamine-serotonin system stabilizer is aripiprazole or a metabolite thereof. Another preferred carbostyryl derivative of the present invention that is a dopamine-serotonin system stabilizer is a metabolite of aripiprazole called dehydroaripiprazole, also known as OPC-14857. Other such metabolites of aripiprazole included within the present invention are shown in Figure 8. Preferred metabolites are shown in Figure 8 indicated by the following designations: OPC-14857, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD.

Aripiprazole, also called 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydro-2(1H)-quinolinone, is a carbostyryl compound and is useful for treating schizophrenia (EP 0 367 141, U.S. Patent No. 5,006,528). Aripiprazole is also known as

7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyryl, Abilify, OPC-14597, OPC-31 and BMS-337039. Aripiprazole possesses 5-HT_{1A} receptor agonist activity, and is known as useful compound for treating
5 types of depression and refractory depressions, such as endogeneous depression, major depression, melancholia and the like (WO 02/060423, U. S. Patent Application 2002/0173513A1). Aripiprazole has activity as an
10 agonist at the serotonin receptors and dopamine receptors, and acts as an agonist or partial agonist at the serotonin 5-HT_{1A} receptor and as an agonist or partial agonist at the dopamine D₂ receptor. Aripiprazole is a dopamine-serotonin system stabilizer. Metabolites of aripiprazole are included within the
15 scope of the present invention. One such metabolite of aripiprazole is called dehydroaripiprazole. Other such metabolites of aripiprazole included within the present invention are shown in Figure 8. Preferred metabolites are shown in Figure 8 indicated by the following
20 designations: OPC-14857, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD.

The at least one serotonin reuptake inhibitor used in the present invention includes but is not limited to the following: fluoxetine, duloxetine,
25 venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof. In a preferred embodiment, the pharmaceutical composition comprises aripiprazole and citalopram in a

pharmaceutically acceptable carrier.

The novel compositions of present invention comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier may be combined in one dosage form, for example a pill. Alternatively the at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and the at least one serotonin reuptake inhibitor may be in separate dosage forms, each in a pharmaceutically acceptable carrier. These compositions are administered to a patient with a mood disorder, particularly depression or major depressive disorder, in an amount and dosage regimen effective to treat the mood disorder.

Accordingly, it is an object of the present invention to provide a pharmaceutical composition useful for treating a mood disorder.

It is an object of the present invention to provide a composition useful for treating a mood disorder, wherein the mood disorder is depression or major depressive disorder.

It is another object of the present invention to provide a composition comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier.

Yet another object of the present invention is to provide a composition comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier, wherein the carbostyryl derivative is aripiprazole or a metabolite thereof.

Yet another object of the present invention is to provide a composition comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier, wherein the carbostyryl derivative is aripiprazole and the serotonin reuptake inhibitor is citalopram.

Yet another object of the present invention is to provide a composition comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor, wherein the carbostyryl derivative with activity as a dopamine-serotonin system stabilizer is a metabolite of aripiprazole and is dehydroaripiprazole (OPC-14857), DM-1458, DM-1451, DM-1452, DM-1454 or DCPD.

Yet another object of the present invention is to provide a composition comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin

reuptake inhibitor, wherein the carbostyryl derivative is dehydroaripiprazole.

It is an object of the present invention to provide a use of a composition useful for treating a mood disorder in the preparation of a medicament for treatment of a mood disorder, wherein the mood disorder is depression or major depressive disorder.

It is another object of the present invention to provide a use of a composition comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier in the preparation of a medicament for treatment of a mood disorder.

Yet another object of the present invention is to provide a use of a composition comprising a carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier in the preparation of a medicament for treatment of mood disorders, wherein the carbostyryl derivative is aripiprazole or a metabolite thereof.

Yet another object of the present invention is to provide a use of a composition comprising a carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier in the preparation of a medicament for

treatment of mood disorders, wherein at least one carbostyryl derivative is aripiprazole and at least one serotonin reuptake inhibitor is citalopram.

Yet another object of the present invention
5 is to provide a use of a composition comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor pharmaceutically acceptable carrier in the preparation of a medicament
10 for treatment of mood disorders, wherein the carbostyryl derivative with activity as a dopamine-serotonin system stabilizer is a metabolite of aripiprazole and is dehydroaripiprazole (OPC-14857), DM-1458, DM-1451, DM-1452, DM-1454 or DCP.

15 Yet another object of the present invention is to provide a use of a composition comprising a carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable
20 carrier in the preparation of a medicament for treatment of mood disorders, wherein the carbostyryl derivative is dehydroaripiprazole.

It is an object of the present invention to provide a method for treating a mood disorder.

25 It is an object of the present invention to provide a method for treating a mood disorder wherein the mood disorder is depression or major depressive disorder.

It is another object of the present invention to provide a method for treating a mood disorder comprising administration to a patient with a mood disorder of a composition comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier.

It is another object of the present invention to provide a method for treating a mood disorder comprising administration to a patient with a mood disorder of a composition comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor together in a pharmaceutically acceptable carrier, wherein the carbostyryl derivative is aripiprazole or a metabolite thereof.

It is another object of the present invention to provide a method for treating major depressive disorder comprising administration to a patient with major depressive disorder of a composition comprising a carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor together with a pharmaceutically acceptable carrier, wherein the carbostyryl derivative is aripiprazole and the serotonin reuptake inhibitor is citalopram.

Still another object of the present invention

is to provide a method for treating a mood disorder comprising administration to a patient with a mood disorder of a composition comprising at least one carbostyryl derivative with activity as a dopamine-
5 serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier, wherein the carbostyryl derivative is a metabolite of aripiprazole and is dehydroaripiprazole (OPC-14857), DM-1458, DM-1451, DM-1452, DM-1454 or
10 DCPD.

Yet another object of the present invention is to provide a method for treating major depressive disorder comprising administration to a patient with major depressive disorder of a composition comprising
15 at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier, wherein the mood disorder is major depressive disorder.

20 It is another object of the present invention to provide a method for treating major depressive disorder comprising administration to a patient with major depressive disorder of a composition comprising at least one carbostyryl derivative with activity as a
25 dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier.

It is another object of the present invention

to provide a method for treating major depressive disorder comprising administration to a patient with major depressive disorder of a composition comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor together with a pharmaceutically acceptable carrier, wherein the carbostyryl derivative is aripiprazole or a metabolite thereof.

Still another object of the present invention is to provide a method for treating major depressive disorder comprising administration to a patient with major depressive disorder of a composition comprising at least one carbostyryl derivative with activity as a dopamine-serotonin system stabilizer and at least one serotonin reuptake inhibitor in a pharmaceutically acceptable carrier, wherein the carbostyryl derivative is a metabolite of aripiprazole and is dehydro-aripiprazole (OPC-14857), DM-1458, DM-1451, DM-1452, DM-1454 or DCPD.

These and other objects, advantages, and uses of the present invention will reveal themselves to one of ordinary skill in the art after reading the detailed description of the preferred embodiments and the attached claims.

BRIEF DESCRIPTION OF DRAWINGS

Figure 1 is the thermogravimetric/

differential thermogram of the aripiprazole hydrate A obtained in Reference Example 4.

Figure 2 is the ^1H -NMR spectrum (DMSO- d_6 , TMS) of the aripiprazole hydrate A obtained in Reference
5 Example 4.

Figure 3 is the powder X-ray diffraction diagram of the aripiprazole hydrate A obtained in Reference Example 4.

Figure 4 is the ^1H -NMR spectrum (DMSO- d_6 , TMS)
10 of the aripiprazole anhydride crystals B obtained in Example 1.

Figure 5 is the powder X-ray diffraction diagram of the aripiprazole anhydride crystals B obtained in Example 1.

15 Figure 6 is the thermogravimetric/differential thermogram of the aripiprazole hydrate A obtained in Reference Example 3.

Figure 7 is the powder X-ray diffraction diagram of aripiprazole hydrate obtained in Reference
20 Example 3.

Figure 8 is a schematric representation of the chemical structures of aripiprazole and metabolites thereof. Some of the metabolites may be formed through other possible pathways; for example, DM-1431 could be
25 formed by N-dealkylation of DM-1451 and DM-1459.


DETAILED DESCRIPTION OF THE INVENTION

The pharmaceutical composition of the present

invention comprises a first ingredient comprising a carbostyryl derivative active as a dopamine-serotonin system stabilizer and a second ingredient comprising a serotonin reuptake inhibitor, in a pharmaceutically acceptable carrier. The pharmaceutical compositions of the present invention are useful in treating mood disorders, including depression and major depressive disorder.

The pharmaceutical composition: the first ingredient

The first ingredient comprises a carbostyryl derivative active as a dopamine-serotonin system stabilizer. Such carbostyryl derivative has activity as an agonist or partial agonist at some serotonin receptors and some dopamine receptors, preferably as an agonist or partial agonist at the serotonin 5-HT_{1A} receptor and as an agonist or partial agonist at the dopamine D₂ receptor. Carbostyryl derivatives are described in U.S. Patent 5,006,528 and U.S. published patent application 2002/0173513A1. In one embodiment of the present invention, the carbostyryl derivatives represented by the following formula (1) are used:



wherein the carbon-carbon bond between 3- and 4-positions in the carbostyryl skeleton is a single or a double bond.

In a preferred embodiment, this activity of the carbostyryl derivative is as an agonist or partial agonist at the 5-HT_{1A} receptor and an agonist or partial agonist at the dopamine D₂ receptor subtype. In another preferred embodiment, the carbostyryl derivative to be used as a first component in the present invention is aripiprazole, or a metabolic derivative thereof. Metabolic derivatives of aripiprazole include but are not limited to dehydroaripiprazole, also called OPC-14857. Other metabolic derivatives of aripiprazole include but are not limited to the chemical structures shown in Figure 8 as OPC-14857, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD. All of the aforementioned carbostyryl derivatives may be used as a first component in the practice of the present invention.

Aripiprazole, also called 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydro-2(1H)-quinolinone, is a carbostyryl compound useful as the effective ingredient for treating schizophrenia (JP-A-2-191256, U S. Patent 5,006,528). Aripiprazole is also known as 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyryl, Abilify, OPC-14597, OPC-31 and BMS-337039. Aripiprazole possesses 5-HT_{1A} receptor agonist activity, and is

known as a useful compound for treating types of depression and refractory depression, such as endogenous depression, major depression, melancholia and the like (WO 02/060423A2; Jordan et al. U.S. Patent Application 2002/0173513A1). Aripiprazole has activity as an agonist at serotonin receptors and dopamine receptors, and acts as an agonist or partial agonist at the serotonin 5-HT_{1A} receptor and as an agonist or partial agonist at the dopamine D₂ receptor.

Aripiprazole is an antipsychotic drug having new mechanism of action which is different from that of other atypical antipsychotic drugs (Grunder, G. et al., Arch Gen Psychiatry, 60(10), pp 974-977, 2003). The available typical and atypical antipsychotic drugs act as antagonists at the dopamine-D₂ receptors. In contrast, aripiprazole acts as a partial agonist at the dopamine D₂ receptor (By Ishigooka Jyunya and Inada Ken, RINSHO SEISHIN YAKURI, Vol. 4, pp 1653-1664 (2001); Burris, K. D. et al., J. Pharmacol. Exp. Ther., 302, pp 381-389 (2002)). In addition to the partial agonist action at dopamine-D₂ receptors, aripiprazole has activity as a partial agonist at the serotonin 5-HT_{1A} receptors, as well as antagonist action at serotonin 5-HT_{2A} receptors. Accordingly, aripiprazole is a drug belonging to new category defined as a dopamine-serotonin system stabilizer (dopamine-serotonin stabilizer (Burris, K. D. et al., J. Pharmacol, Exp. Ther., 302, pp 381-389, 2002; Jordan, S. et al., Eur.

J. Pharmacol. 441, pp 137-140, 2002; Grunder, G. et al., Arch Gen Psychiatry, 60(10), pp 974-977, 2003).

Methods of Preparing Aripiprazole

Aripiprazole and aripiprazole metabolites to
5 be used in the present invention may be any of form,
for example, free bases, polymorphisms of every type of
crystal, hydrate, salts (acid addition salts, etc.) and
the like. Among of these forms, aripiprazole anhydride
crystals B is a preferred form.

10 As to method for preparing the aripiprazole
anhydride crystals B, for example it is prepared by
heating aripiprazole hydrate A as follows.

Aripiprazole Hydrate A

The aripiprazole hydrate A having the
15 physicochemical properties shown in (1) - (5) as
follows:

(1) It has an endothermic curve which is
substantially identical to the thermogravimetric/
differential thermal analysis (heating rate 5°C/min)
20 endothermic curve shown in Figure 1. Specifically, it
is characterized by the appearance of a small peak at
about 71°C and a gradual endothermic peak around 60°C
to 120°C.

(2) It has an ¹H-NMR spectrum which is
25 substantially identical to the ¹H-NMR spectrum (DMSO-d₆,
TMS) shown in Figure 2. Specifically, it has

characteristic peaks at 1.55-1.63 ppm (m, 2H), 1.68-1.78 ppm (m, 2H), 2.35-2.46 ppm (m, 4H), 2.48-2.56 ppm (m, 4H + DMSO), 2.78 ppm (t, $J = 7.4$ Hz, 2H), 2.97 ppm (brt, $J = 4.6$ Hz, 4H), 3.92 ppm (t, $J = 6.3$ Hz, 2H),
5 6.43 ppm (d, $J = 2.4$ Hz, 1H), 6.49 ppm (dd, $J = 8.4$ Hz, $J = 2.4$ Hz, 1H), 7.04 ppm (d, $J = 8.1$ Hz, 1H), 7.11-7.17 ppm (m, 1H), 7.28-7.32 ppm (m, 2H) and 10.00 ppm (s, 1H).

(3) It has a powder x-ray diffraction
10 spectrum which is substantially identical to the powder x-ray diffraction spectrum shown in Figure 3. Specifically, it has characteristic peaks at $2\theta = 12.6^\circ$, 15.4° , 17.3° , 18.0° , 18.6° , 22.5° and 24.8° .

(4) It has clear infrared absorption bands at
15 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963 and 784 cm^{-1} on the IR (KBr) spectrum.

(5) It has a mean particle size of 50 μm or less.

Method for preparing Aripiprazole Hydrate A

20 Aripiprazole hydrate A is prepared by milling conventional aripiprazole hydrate. Conventional milling methods can be used to mill conventional aripiprazole hydrate. For example, conventional aripiprazole hydrate can be milled in a milling
25 machine. A widely used milling machine such as an atomizer, pin mill, jet mill or ball mill can be used. Among of these, the atomizer is preferably used.

Regarding the specific milling conditions when using an atomizer, a rotational speed of 5000-15000 rpm could be used for the main axis, for example, with a feed rotation of 10-30 rpm and a screen hole size of 1-5 mm.

The mean particle size of the aripiprazole hydrate A obtained by milling may be normally 50 μm or less, preferably 30 μm or less. Mean particle size can be ascertained by the particle size measuring method described hereinafter.

Aripiprazole Anhydride Crystals B

"Aripiprazole anhydride crystals B" of the present invention have the physicochemical properties given in (6)-(10) below.

(6) They have an ^1H -NMR spectrum which is substantially identical to the ^1H -NMR spectrum ($\text{DMSO}-d_6$, TMS) shown in Figure 4. Specifically, they have characteristic peaks at 1.55-1.63 ppm (m, 2H), 1.68-1.78 ppm (m, 2H), 2.35-2.46 ppm (m, 4H), 2.48-2.56 ppm (m, 4H + DMSO), 2.78 ppm (t, $J = 7.4$ Hz, 2H), 2.97 ppm (brt, $J = 4.6$ Hz, 4H), 3.92 ppm (t, $J = 6.3$ Hz, 2H), 6.43 ppm (d, $J = 2.4$ Hz, 1H), 6.49 ppm (dd, $J = 8.4$ Hz, $J = 2.4$ Hz, 1H), 7.04 ppm (d, $J = 8.1$ Hz, 1H), 7.11-7.17 ppm (m, 1H), 7.28-7.32 ppm (m, 2H) and 10.00 ppm (s, 1H).

(7) They have a powder x-ray diffraction spectrum which is substantially identical to the powder x-ray diffraction spectrum shown in Figure 5.

Specifically, they have characteristic peaks at $2\theta = 11.0^\circ, 16.6^\circ, 19.3^\circ, 20.3^\circ$ and 22.1° .

(8) They have clear infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960 and
5 779 cm^{-1} on the IR (KBr) spectrum.

(9) They exhibit an endothermic peak near about 141.5°C in thermogravimetric/differential thermal analysis (heating rate $5^\circ\text{C}/\text{min}$).

(10) They exhibit an endothermic peak near
10 about 140.7°C in differential scanning calorimetry (heating rate $5^\circ\text{C}/\text{min}$).

When the small particle size is required for solid preparation, such as tablets and other solid dose formulations including for example flash melt formula-
15 tions, the mean particle size is preferably $50\text{ }\mu\text{m}$ or less.

Method for preparing Aripiprazole Anhydride Crystals B

The aripiprazole anhydride crystals B of the present invention are prepared for example by heating
20 the aforementioned aripiprazole hydrate A at $90\text{--}125^\circ\text{C}$. The heating time is generally about 3-50 hours, but cannot be stated unconditionally, because it differs depending on heating temperature. The heating time and heating temperature are inversely related, so that for
25 example when the heating time is longer, then the heating temperature is lower, and when the heating temperature is higher then the heating time is shorter.

Specifically, if the heating temperature of aripiprazole hydrate A is 100°C, the heating time may be 18 hours or more, or preferably about 24 hours. If the heating temperature of aripiprazole hydrate A is 120°C, on the other hand, the heating time may be about 3 hours. The aripiprazole anhydride crystals B of the present invention can be prepared with certainty by heating aripiprazole hydrate A for about 18 hours at 100°C, and then heating it for about 3 hours at 120°C. The aripiprazole anhydride crystals B of the present invention can also be obtained if the heating time is extended still further, but this method may not be economical.

When small particle size is not required for the formulation, e.g., when drug substance is being prepared for injectable or oral solution formulations, aripiprazole anhydride crystals B can be also obtained by the following process.

Aripiprazole anhydride crystals B of the present invention are prepared for example by heating conventional aripiprazole anhydride crystals at 90-125°C. The heating time is generally about 3-50 hours, but cannot be stated unconditionally because it differs depending on heating temperature. The heating time and heating temperature are inversely related, so that for example if the heating time is longer, the heating temperature is lower, and if the heating time is shorter, the heating temperature is higher.

Specifically, if the heating temperature of the aripiprazole anhydride crystals is 100°C, the heating time may be about 4 hours, and if the heating temperature is 120°C the heating time may be about 3 hours.

Furthermore, aripiprazole anhydride crystals B of the present invention are prepared for example, by heating conventional aripiprazole hydrate at 90-125° C. The heating time is generally about 3-50 hours, but cannot be stated unconditionally because it differs depending on heating temperature. The heating time and heating temperature are inversely related, so that for example, if the heating time is longer, the heating temperature is lower, and if the heating time is shorter, the heating temperature is higher. Specifically, if the heating temperature of the aripiprazole hydrate is 100°C, the heating time may be about 24 hours, and if the heating temperature is 120°C the heating time may be about 3 hours.

The aripiprazole anhydride crystals which are the raw material for preparing the aripiprazole anhydride crystals B of the present invention are prepared for example by Method a or b below.

"Method a": Process for preparing crude crystals of Aripiprazole

Conventional aripiprazole anhydride crystals are prepared by well-known methods, as described in

Example 1 of Japanese Unexamined Patent Publication No. 191256/1990.

7-(4-bromobutoxy)-3,4-dihydrocarbostyryl, is reacted with 1-(2,3-dichlorophenyl)piperazine and the
5 thus obtained crude aripiprazole crystals are recrystallized from ethanol.

"Method b": Process for preparing conventional Aripiprazole Anhydride

The Method b is described in the Proceedings
10 of the 4th Joint Japanese-Korean Symposium on Separation Technology (October 6-8, 1996).

The aripiprazole hydrate which is the raw material for preparing the aripiprazole anhydride crystals B of the present invention is prepared for
15 example by Method c below.

"Method c": Method for preparing conventional Aripiprazole Hydrate

Aripiprazole hydrate is easily obtained by dissolving the aripiprazole anhydride crystals obtained
20 by Method a above in a hydrous solvent, and heating and then cooling the resulting solution. Using this method, aripiprazole hydrate is precipitated as crystals in the hydrous solvent.

An organic solvent containing water is
25 usually used as the hydrous solvent. The organic solvent may be preferable one which is miscible with

water, for example an alcohol such as methanol, ethanol, propanol or isopropanol, a ketone such as acetone, an ether such as tetrahydrofuran, dimethylformamide, or a mixture thereof, ethanol is particularly desirable. The amount of water in the hydrous solvent may be 10-25% by volume of the solvent, or preferably close to 20% by volume.

Aripiprazole can easily form an acid addition salt with a pharmaceutically acceptable acid. As to such acid, for example, an inorganic acid, such as sulfuric acid, nitric acid, hydrochloric acid, phosphoric acid, hydrobromic acid, etc.; an organic acid such as, acetic acid, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid, succinic acid, etc. can be exemplified. Similar to aripiprazole of free forms, these acid addition salts can also be used as the active ingredient compounds in the present invention.

The objective compound thus obtained through each one of production steps, is separated from the reaction system by usual separation means, and can be further purified. As to the separation and purification means, for example, distillation method, solvent extraction method, dilution method, recrystallization method, column chromatography, ion-exchange chromatography, gel chromatography, affinity chromatography, preparative thin-layer chromatography

and the like can be exemplified.

The pharmaceutical composition: the second ingredient

In the composition of the present invention, a serotonin reuptake inhibitor is used as the second
5 ingredient. Compounds which function as serotonin reuptake inhibitors can be widely used as the serotonin reuptake inhibitors and are known to one of ordinary skill in the art.

Among the serotonin reuptake inhibitors,
10 those having IC_{50} value (a concentration of the drug that inhibits serotonin reuptake by about 50%), measured by the method of Wong et al. (Neuropsychopharmacology, 8, pp 337-344 (1993)), the standard pharmacological assay method, is about 1000 nM
15 or lower is preferable.

As to such serotonin reuptake inhibitors, for example, fluvoxamine (5-methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone-O-(2-aminoethyl)oxime), fluoxetine (N-methyl-3-(p-trifluoromethylphenoxy)-3-
20 phenylpropylamine), paroxetine (trans-(-)-3-[(1,3-benzodioxol-5-yl)oxy)methyl]-4-(4-fluorophenyl)-piperidine), sertraline (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthylamine hydrochloride), venlafaxine,
25 milnacipran (N,N-diethyl-2-aminomethyl-1-phenylcyclopropanecarboxamide), citalopram, escitalopram, duloxetine and the like may be used.

The serotonin reuptake inhibitor may be either in the form of a free base or a salt (an acid addition salt or the like). Further, the serotonin reuptake inhibitor may be either a racemic
5 modifications or R and S enantiomers.

The serotonin reuptake inhibitors may be either a single use of one serotonin reuptake inhibitor, and in case of need, two or more of the serotonin reuptake inhibitors may be used in combina-
10 tion. Use of one serotonin reuptake inhibitor is preferred.

The serotonin reuptake inhibitor can easily form an acid addition salt with a pharmaceutically acceptable acid. As to such acid, for example, an
15 inorganic acid, such as sulfuric acid, nitric acid, hydrochloric acid, phosphoric acid, hydrobromic acid, etc.; an organic acid such as, acetic acid, p-toluene-sulfonic acid, methanesulfonic acid, oxalic acid, maleic acid, fumaric acid, malic acid, tartaric acid,
20 citric acid, benzoic acid, succinic acid, etc. can be exemplified. Similar to the reuptake inhibitor of free forms, these acid addition salts can be also used as the active ingredient compounds in the present invention.

25 Among the serotonin reuptake inhibitors, a compound having acidic group can easily form salt by reacting with a pharmaceutically acceptable basic compound. As to such basic compound, a metal

hydroxide, for example, sodium hydroxide, potassium hydroxide, lithium hydroxide, calcium hydroxide and the like; an alkali metal carbonate or bicarbonate, for example sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate and the like; a metal alcoholate, for example sodium methylate, potassium ethylate and the like can be exemplified.

The thus obtained salt form of serotonin reuptake inhibitor is separated from the reaction system by usual separation means, and can be further purified. As to the separation and purification means, for example, distillation method, solvent extraction method, dilution method, recrystallization method, column chromatography, ion-exchange chromatography, gel chromatography, affinity chromatography, preparative thin-layer chromatography and the like can be exemplified.

Combination of the first ingredient with the second ingredient

As to combination of carbostyryl derivatives with activity as dopamine-serotonin system stabilizers, non-limiting examples of aripiprazole and dehydroaripiprazole are described herein. When aripiprazole is combined with at least one serotonin reuptake inhibitor, the following are non-limiting examples of such combinations: aripiprazole/fluoxetine, aripiprazole/duloxetine, aripiprazole/venlafaxine,

aripiprazole/milnacipran, aripiprazole/citalopram, aripiprazole/fluvoxamine, aripiprazole/paroxetine, and aripiprazole/sertraline. A preferred embodiment comprises a combination of aripiprazole/citalopram.

5 In another embodiment of the present invention, aripiprazole, or a metabolite thereof may be combined with more than one serotonin reuptake inhibitor. Metabolites of aripiprazole that may be used in the present invention include but are not
10 limited to OPC-14857, DM-1458, DM-1451, DM-1452, DM-1454 and DCPD as shown in Figure 8. Any one of these metabolites may be used in the present invention. The following sentences describe a combination of dehydroaripiprazole with specific serotonin reuptake
15 inhibitors, however it is to be understood that any one of DM-1458, DM-1451, DM-1452, DM-1454 or DCPD, as shown in Figure 8, could be substituted for dehydroaripiprazole in these disclosed combinations. Dehydroaripiprazole (also called OPC-14857 in Figure 8)
20 is a preferred metabolite of aripiprazole. As to combination of dehydroaripiprazole with serotonin reuptake inhibitor, the following are non-limiting examples of such combinations:
dehydroaripiprazole/fluoxetine,
25 dehydroaripiprazole/duloxetine,
dehydroaripiprazole/venlafaxine,
dehydroaripiprazole/milnacipran,
dehydroaripiprazole/citalopram,

dehydroaripiprazole/fluvoxamine,
dehydroaripiprazole/paroxetine, and
dehydroaripiprazole/sertraline. A preferred embodiment
comprises a combination of dehydroaripiprazole and
5 citalopram.

Method of Treating a Mood Disorder, Especially Major
Depressive Disorder

Patients with mood disorders may be treated
with the compositions of the present invention. A
10 preferred disorder treated with the method and
compositions of the present invention is depression or
major depressive disorder. Treatment comprises
administration of the compositions of the present
invention to a patient with a mood disorder such as
15 depression or major depressive disorder, in an amount
and dose regimen effective to treat the mood disorder.

Dosage

Dosage of the drug used in the present
invention is decided by considering the properties of
20 each constituting drug to be combined, the properties
of drugs being after combination and symptoms of the
patient (existence of other diseases beside mood
disorders such as depression or major depressive
disorder). General outlines of the dosage can be
25 applied the following guidelines.

Aripiprazole or a metabolite, such as

dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 or DCPD: generally about 0.1 to 100 mg/once a day (or about 0.05 to about 50 mg/twice a day), preferably about 1 to 30 mg/once a day (or about 0.5 to about 15 mg/twice a day).

The aripiprazole, or a metabolite thereof, may be combined with at least one of any of the following SRIs at the dosage ranges indicated:

Fluoxetine: generally about 1 to about 80 mg/once a day, preferably about 10 to about 40 mg/once a day;

Duloxetine: generally about 1 to 160 mg/once a day (or 80 mg/twice a day), preferably about 5 to about 20 mg/once a day;

Venlafaxine: generally about 10 to 150 mg/1 to 3 times a day, preferably about 25 to 125 mg/3 times a day;

Milnacipran: generally about 10 to 100 mg/1 to 2 times a day, preferably about 25 to about 50 mg/twice a day;

Citalopram: generally about 5 to about 50 mg/once a day, preferably about 10 to about 30 mg/once a day;

Escitalopram: generally about 5 to about 30 mg/once a day, preferably about 10 to about 20 mg/once a day;

Fluvoxamine: generally about 20 to 500 mg/once a day, preferably about 50 to 300 mg/once a

day;

Paroxetine: generally about 20 to about 50 mg/once a day, preferably about 20 to about 30 mg/once a day; or

5 Sertraline: generally, about 20 to about 500 mg/once a day, preferably about 50 to about 200 mg/once a day.

Generally, the weight ratio of the first ingredient to the second ingredient is selected in
10 accordance with the above-mentioned guideline. As to the ratio of the first ingredient and the second ingredient, if the first ingredient is about 1 part by weight of the former, the second ingredient is used about 0.01 to about 500 parts by weight, preferably
15 about 0.1 to about 100 parts by weight.

Pharmaceutically Acceptable Carriers

Pharmaceutically acceptable carriers include diluents and excipients generally used in pharmaceutical preparations, such as fillers,
20 extenders, binders, moisturizers, disintegrators, surfactant, and lubricants.

The pharmaceutical composition of the present invention may be formulated as an ordinary pharmaceutical preparation, for example in the form of
25 tablets, flash melt tablets, pills, powder, liquid, suspension, emulsion, granules, capsules, suppositories or injection (liquid, suspension, etc.), troches,

intranasal spray percutaneous patch and the like.

In case of shaping to tablet formulation, a wide variety of carriers that are known in this field can be used. Examples include lactose, saccharose, sodium chloride, glucose, urea, starch, xylitol, mannitol, erythritol, sorbitol, calcium carbonate, kaolin, crystalline cellulose, silic acid and other excipients; water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate, polyvinyl pyrrolidone and other binders; dried starch, sodium alginate, agar powder, laminaran powder, sodium hydrogencarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose and other disintegrators; white sugar, stearin, cacao butter, hydrogenated oil and other disintegration inhibitors; quaternary ammonium salt, sodium lauryl sulfate and other absorption accelerator; glycerine, starch and other moisture retainers; starch, lactose, kaolin, bentonite, colloidal silic acid and other adsorbents; and refined talc, stearate, boric acid powder, polyethylene glycol and other lubricants and the like. Tablets can also be formulated if necessary as tablets with ordinary coatings, such as sugar-coated tablets, gelatin-coated tablets, enteric coated tablets and film coated tablets, as well as double tablets and multilayered tablets.

In case of shaping to pills, a wide variety of carriers that are known in this field can be used. Examples include glucose, lactose, starch, cacao butter, hardened vegetable oil, kaolin, talc and other
5 excipients; gum arabic powder, traganth powder, gelatin, ethanol and other binders; and laminaran, agar and other disintegrators and the like.

In case of shaping to a suppository formulation, a wide variety of carriers that are known
10 in the field can be used. Examples include polyethylene glycol, cacao butter, higher alcohol, esters of higher alcohol, gelatin semi-synthetic glyceride and the like.

Capsules are prepared according to ordinary
15 methods by mixing carbostyryl derivatives such as aripiprazole anhydride crystals as the first ingredient and serotonin reuptake inhibitor as the second ingredient, and the various carriers described above and packing them in hard gelatin capsules, soft
20 capsules hydroxypropylmethyl cellulose capsules (HPMC capsules) and the like.

In addition, colorants, preservatives, perfumes, flavorings, sweeteners and the like as well as other drugs may be contained in the pharmaceutical
25 composition.

The amounts of the first ingredient and the second ingredient to be contained in the pharmaceutical composition of the present invention are suitably

selected from a wide range depending on the diseases to be treated. Generally, about 1 to 70 parts by weight, preferably about 1 to 30 parts by weight of the first ingredient and the second ingredient in the total amount on the basis of the pharmaceutical composition.

The methods for administration of the pharmaceutical composition of the present invention are not specifically restricted. The composition is administered depending on each type of preparation forms, and the age, gender and other condition of the patient (degree and conditions of the disease, etc.). For example, tablets, pills, liquids, suspensions, emulsions, granules and capsules are administered orally. In case of injection preparation, it is administered intravenously by either singly or mixed with a common auxiliary liquid such as solutions of glucose or amino acid. Further, if necessary, the injection preparation is singly administered intracutaneously, subcutaneously or intraperitoneally. In case of a suppository, it is administered intrarectally.

Administration forms of the pharmaceutical composition of the present invention may be any type by which the effective levels of both carbostyryl derivatives and serotonin reuptake inhibitors can be provide in vivo at the same time. In one embodiment, a carbostyryl derivative together with a serotonin reuptake inhibitor are contained in one pharmaceutical

composition and this composition may be administered. On the other hand, each one of carbostyryl derivative and a serotonin reuptake inhibitor are contained individually in a pharmaceutical preparation

5 respectively, and each one of these preparations may be administered at the same time or in suitable intervals.

Dosage of the pharmaceutical composition of the present invention for treating and improving depression or major depressive disorder may be used
10 relatively in a small amount, because the composition possesses excellent efficacy. Therefore the composition has fewer side-effects and an excellent safety profile.

The pharmaceutical composition of the present
15 invention is quite effective for treating or improving mood disorders such as depressive symptoms, depression, refractory depression, major depressive disorder and the like.

The pharmaceutical composition of the present
20 invention can be manifest in a wide range of neurotransmission accommodation actions. As a result, the composition of the present invention establishes pseudo-homeostatic dopaminergic and serotonergic neurotransmission (as a result of partial agonism),
25 which, as a result of neuropathophysiological processes has ceased to function normally.

The mood disorders which can be treated by the pharmaceutical composition of the present invention

includes the mood disorders being classified in "Diagnostic and Statistical Manual of Mental Disorders" Fourth Edition (DSM-IV) published by the American Psychiatric Association. These mood disorders include, for example, major depressive disorder, all mood disorders, schizoaffective disorder, dementia with depressive symptoms and the like. A preferred disorder to be treated with the present invention is major depressive disorder.

10 The pharmaceutical composition of the present invention is useful for treating major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory
15 depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury and the like. In
20 addition to the methods for treatment described herein, additional disclosure for designing clinical studies is provided in J. Clin. Psychiatry, 2002, 63:(12), pp 1164-1170; J. Clin. Psychiatry, 2002, 63:(8), pp 733-736; and J. Clin. Psychiatry, 2002, 63:(5), pp 391-395.

25 EXAMPLES

The present invention will be explained more in detail by illustrating Reference Examples, Example

and Formulation Sample Examples. First, analytical methods are explained.

Analytical Methods

(1) The ^1H -NMR spectrum was measured in DMSO-
5 d_6 by using TMS as the standard.

(2) Powder X-ray Diffraction

By using RAD-2B diffraction meter
manufactured by Rigaku Denki, the powder x-ray
diffraction pattern was measured at room temperature by
10 using a Cu Ka filled tube (35 kV 20mA) as the x-ray
source with a wide-angle goniometer, a 1° scattering
slit, an 0.15 mm light-intercepting slit, a graphite
secondary monochromator and a scintillation counter.
Data collection was done in 2θ -continuous scan mode at a
15 scan speed of $5^\circ/\text{minute}$ in scan steps of 0.02° in the
range of 3° to 40° .

(3) The IR spectrum was measured by the KBr
method.

(4) Thermogravimetric/Differential Thermal 20 Analysis

Thermogravimetric/differential thermal
analysis was measured by using SSC 5200 control unit
and TG/DTA 220 simultaneous differential thermal/
thermogravimetric measuring unit manufactured by Seiko
25 Corp. Samples (5 - 10 mg) were placed in open aluminum
pans and heated at from 20°C to 200°C in a dry nitrogen
atmosphere at a heating rate of $5^\circ\text{C}/\text{minute}$. α -Alumina

was used as the standard substance.

(5) Differential Scanning Calorimetry

Thermogravimetric/differential thermal analysis was measured by using SSC 5200 control unit and DSC 220C differential scanning calorimeter manufactured by Seiko Corp. Samples (5 - 10 mg) were placed in crimped aluminum pans and heated from 20°C to 200°C in a dry nitrogen atmosphere at a heating rate of 5°C/minute. α -Alumina was used as the standard substance.

(6) Particle Size Measurement

The particles (0.1 g) to be measured were suspended in a 20 ml n-hexane solution of 0.5 g soy lecithin, and particle size was manufactured by using a size distribution measuring meter (Microtrack HRA, manufactured by Microtrack Co.).

Reference Example 1

7-(4-Cholorobutoxy)-3,4-dihydrocarbostyryl (19.4 g) and monohydrochloride 16.2 g of 1-(2,3-dichlorophenyl)piperadine 1 hydrochloride were added to a solution of 8.39 g of potassium carbonate dissolved in 140 ml of water, and refluxed for 3 hours under agitation. After the reaction was complete, the mixture was cooled and the precipitated crystals collected by filtration. These crystals were dissolved in 350 ml of ethyl acetate, and about 210 ml of water/ethyl acetate azeotrope was removed under reflux.

The remaining solution was cooled, and the precipitated crystals were collected by filtration. The resulting crystals were dried at 60°C for 14 hours to obtain 20.4 g (74.2%) of crude product of aripiprazole.

5 The crude product of aripiprazole (30 g) obtained above was recrystallized from 450 ml of ethanol according to the methods described in Japanese Unexamined Patent Publication No. 191256/1990, and the resulting crystals were dried at 80°C for 40 hours to
10 obtain aripiprazole anhydride crystals. The yield was 29.4 g (98.0%).

 The melting point (mp) of these aripiprazole anhydride crystals was 140°C, which is identical to the melting point of the aripiprazole anhydride crystals
15 described in Japanese Unexamined Patent Publication No. 191256/1990.

Reference Example 2

 The crude product of aripiprazole (6930 g) obtained in Reference Example 1 was heat dissolved by
20 heating in 138 liters of hydrous ethanol (water content 20% by volume) according to the method presented at the 4th Joint Japanese-Korean Symposium on Separation Technology, the solution was gradually (2-3 hours) cooled to room temperature, and then was chilled to
25 near 0°C. The precipitated crystals were collected by filtration, about 7200 g of aripiprazole hydrate (wet-state).

The wet-state aripiprazole hydrate crystals obtained above were dried at 80°C for 30 hours to obtain 6480 g (93.5%) of aripiprazole anhydride crystals. The melting point (mp) of these crystals was
5 139.5°C.

Further, the crystalline form of these crystals was colorless flake.

The water content of the crystals were confirmed by the Karl Fischer method, the moisture
10 value was 0.03%, thus the crystals were confirmed as anhydrous product.

Reference Example 3

The aripiprazole hydrate (820 g) in wet state obtained from Reference Example 2 was dried at 50°C for
15 2 hours to obtain 780 g of aripiprazole hydrate crystals. The moisture value of the crystals had a moisture value was 3.82% measured according to the Karl Fischer method. As shown in Figure 6, thermogravimetric/differential thermal analysis
20 revealed endothermic peaks at 75.0, 123.5 and 140.5°C. Because dehydration began near at 70°C, there was no clear melting point (mp) was observed.

As shown in Figure 7, the powder x-ray diffraction spectrum of aripiprazole hydrate obtained
25 by this method exhibited characteristic peaks at $2\theta = 12.6^\circ, 15.1^\circ, 17.4^\circ, 18.2^\circ, 18.7^\circ, 24.8^\circ$ and 27.5° .

The powder x-ray diffraction spectrum of this

aripiprazole hydrate was identical to the powder x-ray diffraction spectrum of aripiprazole hydrate presented at the 4th Joint Japanese-Korean Symposium on Isolation Technology.

5 Reference Example 4

The aripiprazole hydrate crystals (500.3 g) obtained in Reference Example 3 were milled by using a sample mill (small size atomizer). The main axis rotation rate was set to 12,000 rpm and the feed
10 rotation rate to 17 rpm, and a 1.0 mm herringbone screen was used. Milling was finished in 3 minutes, and obtained 474.6 g (94.9%) of powder of aripiprazole hydrate A.

The aripiprazole hydrate A (powder) obtained
15 in this way had a mean particle size of 20-25 μm . The melting point (mp) was undetermined because dehydration was observed beginning near at 70°C.

The aripiprazole hydrate A (powder) obtained above exhibited an ^1H -NMR (DMSO- d_6 , TMS) spectrum which
20 was substantially identical to the ^1H -NMR spectrum shown in Figure 2. Specifically, it had characteristic peaks at 1.55-1.63 ppm (m, 2H), 1.68-1.78 ppm (m, 2H), 2.35-2.46 ppm (m, 4H), 2.48-2.56 ppm (m, 4H + DMSO), 2.78 ppm (t, $J = 7.4$ Hz, 2H), 2.97 ppm (brt, $J = 4.6$ Hz,
25 4H), 3.92 ppm (t, $J = 6.3$ Hz, 2H), 6.43 ppm (d, $J = 2.4$ Hz, 1H), 6.49 ppm (dd, $J = 8.4$ Hz, $J = 2.4$ Hz, 1H), 7.04 ppm (d, $J = 8.1$ Hz, 1H), 7.11-7.17 ppm (m, 1H),

7.28-7.32 ppm (m, 2H) and 10.00 ppm (s, 1H).

The aripiprazole hydrate A (powder) obtained above had a powder x-ray diffraction spectrum which was substantially identical to the powder x-ray diffraction spectrum shown in Figure 3. Specifically, it had characteristic peaks at $2\theta = 12.6^\circ, 15.4^\circ, 17.3^\circ, 18.0^\circ, 18.6^\circ, 22.5^\circ$ and 24.8° . This pattern is different from the powder x-ray spectrum of unmilled aripiprazole hydrate shown in Figure 7.

The aripiprazole hydrate A (powder) obtained above had infrared absorption bands at 2951, 2822, 1692, 1577, 1447, 1378, 1187, 963 and 784 cm^{-1} on the IR (KBr) spectrum.

As shown in Figure 1, the aripiprazole hydrate A (powder) obtained above had a weak peak at 71.3°C in thermogravimetric/differential thermal analysis and a broad endothermic peak (weight loss observed corresponding to one molecule of water) between $60\text{--}120^\circ\text{C}$ which was clearly different from the endothermic curve of unmilled aripiprazole hydrate (see Figure 6).

It will be appreciated that other embodiments and uses will be apparent to those skilled in the art and that the invention is not limited to these specific illustrative examples.

Example 1

The aripiprazole hydrate A (powder) (44.29

kg) obtained in the Reference Example 4 was dried at 100°C for 18 hours by using a hot air dryer and further heated at 120°C for 3 hours, to obtain 42.46 kg (yield; 99.3 %) of aripiprazole anhydride crystals B. These
5 aripiprazole anhydride crystals B had a melting point (mp) of 139.7°C.

The aripiprazole anhydride crystals B obtained above had an ¹H-NMR spectrum (DMSO-d₆, TMS) which was substantially identical to the ¹H-NMR spectrum
10 shown in Figure 4. Specifically, they had characteristic peaks at 1.55-1.63 ppm (m, 2H), 1.68-1.78 ppm (m, 2H), 2.35-2.46 ppm (m, 4H), 2.48-2.56 ppm (m, 4H + DMSO), 2.78 ppm (t, J = 7.4 Hz, 2H), 2.97 ppm (brt, J = 4.6 Hz, 4H), 3.92 ppm (t, J = 6.3 Hz, 2H), 6.43 ppm (d,
15 J = 2.4 Hz, 1H), 6.49 ppm (dd, J = 8.4 Hz, J = 2.4 Hz, 1H), 7.04 ppm (d, J = 8.1 Hz, 1H), 7.11-7.17 ppm (m, 1H), 7.28-7.32 ppm (m, 2H) and 10.00 ppm (s, 1H).

The aripiprazole anhydride crystals B obtained above had a powder x-ray diffraction spectrum
20 which was substantially the identical to the powder x-ray diffraction spectrum shown in Figure 5. Specifically, they had characteristic peaks at 2θ = 11.0°, 16.6°, 19.3°, 20.3° and 22.1°.

The aripiprazole anhydride crystals B
25 obtained above had remarkable infrared absorption bands at 2945, 2812, 1678, 1627, 1448, 1377, 1173, 960 and 779 cm⁻¹ on the IR (KBr) spectrum.

The aripiprazole anhydride crystals B

obtained above exhibited an endothermic peak near about
at 141.5°C in thermogravimetric/differential thermal
analysis. The aripiprazole anhydride crystals B
obtained above exhibited an endothermic peak near about
5 at 140.7°C in differential scanning calorimetry.

Example 2

Receptor Binding at the 5-HT_{1A} Receptor

1. Materials and Methods

1.1 Test Compound

10 7-{4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]-
butoxy}-3,4-dihydrocarbostyrl (aripiprazole) was used
as test compound.

1.2 Reference Compounds

15 Serotonin (5-HT) and WAY-100635 (N-[2-[4-(2-
methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridyl)-
cyclohexanecarboxamide, a 5-HT_{1A} receptor antagonist,
manufactured by RBI (Natick, Mass.) were used as
reference compounds.

1.3 Vehicle

20 Dimethyl sulfoxide (DMSO) manufactured by
Sigma Chemical Co. (St. Louis, Mo.) was used as
vehicle.

1.4 Preparation of Test and Reference Compounds

25 Test compound was dissolved in 100% dimethyl
sulfoxide (DMSO) to yield 100 µM stock solutions (final
concentration of DMSO in all tubes containing test
compound was 1%, v/v). All other reference compounds

were prepared by the same method using double-distilled water rather than DMSO.

1.5 Experimental Procedure for the [³⁵S]GTP_γS Binding Assay

5 Test and reference compounds were studied in triplicate at 10 different concentrations (0.01, 0.1, 1, 5, 10, 50, 100, 1000, 10000 and 50000 nM) for their effects upon basal [³⁵S]GTP_γS binding to h5-HT1A CHO cell membranes. Reactions were performed in 5 ml glass test
10 tubes containing 8 μl of test/reference drug mixed with 792 μl of buffer (25 mM Tris HCl, 50 mM NaCl, 5 mM MgCl₂, 0.1 mM EGTA, pH = 7.4) containing GDP (1 μM), [³⁵S]GTP_γS (0.1 nM) and h5-HT1A CHO cell membranes (10 μg protein/reaction; NEN Life Science Products, Boston,
15 Mass.; catalog # CRM035, lot # 501-60024, GenBank # X13556). Reactions proceeded for 60 min at room temperature and were terminated by rapid filtration through Whatman GF/B filter paper, using a Brandel harvester and 4×3 ml ice-cold buffer washes. ³⁵S radio-
20 activity bound to the filter paper was measured using liquid scintillation counting (1272 Clinigamma, LKB/Wallach).

1.6 Experimental Procedure to Determine the Binding Affinity of Test compound (aripiprazole) at the 25 h5-HT1A Receptor

Test compound was studied in triplicate at 10 different concentrations (0.01, 0.1, 1, 10, 50, 100, 500, 1000, 5000 and 10000 nM) to determine its

displacement of [³H]8-OH-DPAT (1 nM; NEN Life Sciences; catalog # NET 929, lot # 3406035, Specific Activity = 124.9 Ci/mmol) binding to h5-HT1A receptors in CHO cell membranes (15 - 20 µg protein; NEN Life Science Products, catalog # CRM035, lot # 501-60024).

Membranes (396 µl) were incubated in 5 ml glass tubes containing [³H]8-OH-DPAT (396 µl), test compound or vehicle (8 µl) and buffer A (50 mM Tris.HCl, 10 mM MgSO₄, 0.5 mM EDTA, 0.1% (w/v) ascorbic acid, pH = 7.4).

All assays proceeded for 60 min at room temperature and were terminated by rapid filtration through Whatman GF/B filter paper (presoaked in buffer B; 50 mM Tris.HCl, pH = 7.4), using a Brandel harvester and 4x1 ml ice-cold washes with buffer B. Non-specific binding was determined in the presence of 10 µM (+)8-OH-DPAT.

1.7 Parameters Determined

Serotonin (5-HT) is a full 5-HT1A receptor agonist which stimulates increases in basal [³⁵S]GTP_γS binding to h5-HT1A receptors in recombinant CHO cell membranes. The test compound was studied at 10 concentrations to determine effects upon basal [³⁵S]GTP_γS binding relative to that produced by 10 µM 5-HT. The relative potency (EC₅₀, 95% confidence interval) and intrinsic agonist activity (% of E_{max} for 10 µM 5-HT) was calculated for each compound by computerized non-linear regression analysis of complete concentration-effect data. The binding affinity of test compound at the h5-HT1A receptor was determined by its ability to prevent

[³H]8-OH-DPAT binding to CHO cell membranes that express this receptor. Non-linear regression analysis of the competition binding data was used to calculate an inhibition constant (IC₅₀, 95% confidence interval), which is the concentration of test compound that occupies half of the h5-HT_{1A} sites specifically bound by [³H]8-OH-DPAT. The affinity of h5-HT_{1A} receptors for test compound (K_i, 95% confidence interval) was calculated by the equation, $K_i = (IC_{50}) / (1 + ([^3H]8-OH-DPAT) / K_d)$, where the K_d for [³H]8-OH-DPAT at h5-HT_{1A} = 0.69 nM (NEN Life Sciences). All estimates of drug binding affinity, potency and intrinsic efficacy at the h5-HT_{1A} receptor were calculated using GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, Calif.).

2. Results

The test compound and 5-HT produced concentration-dependent increases above basal [³⁵S]GTP_γS binding. 1% DMSO tested alone had no effect upon basal or drug-induced [³⁵S]GTP_γS binding.

The test compound (EC₅₀ = 2.12 nM), 5-HT (EC₅₀ = 3.67 nM), potently stimulated basal [³⁵S]GTP_γS binding. Potency and intrinsic agonist efficacy estimates were derived by non-linear regression analysis with correlation coefficients (r²) > 0.98 in each case (Table 1). The test compound exerted partial agonist efficacies in the 65 - 70% range. WAY-100635 produced no significant

change (unpaired Student's t-test) in basal [35 S]GTP $_{\gamma}$ S binding at all concentrations tested (Table 1). WAY-100635 did, however, completely inhibit the effects of 5-HT and test compound upon [35 S]GTP $_{\gamma}$ S binding to h5-HT1A receptors in CHO cell membranes (Table 2). Tables 1 and 2 are shown below.

The test compound demonstrated high affinity binding to h5-HT1A receptors in CHO cell membranes (IC_{50} = 4.03 nM, 95% confidence interval = 2.67 to 6.08 nM; K_i = 1.65 nM, 95% confidence interval = 1.09 to 2.48 nM).

Table 1 Potency (EC_{50}) and Intrinsic Agonist Efficacy (E_{max}) of Test compound and Reference Drugs in a h5-HT1A [35 S]GTP $_{\gamma}$ S CHO-cell Membrane Binding Assay.

Drug	EC_{50} , nM (95% Confidence Interval)	E_{max} (% \pm SEM)	Goodness of Fit (r^2)
Test Compound	2.12 (0.87 to 5.16)	68.13 \pm 3.16	0.986
5-HT	3.67 (1.56 to 8.63)	98.35 \pm 4.47	0.986
WAY-100635	-	-	-

Table 2 Inhibitory Potency (IC_{50}) of WAY-100635 versus
1 μM Concentration of 5-HT and Test compound
in a h5-HT1A [^{35}S]GTP γ S CHO-cell Membrane
Binding Assay.

Drug Combination	WAY-100635 Inhibition Potency, IC_{50} , nM (95% Confidence Interval)	Goodness of Fit (r^2)
5-HT + WAY-100635	217.1 (127.4 to 369.7)	0.988
Test compound + WAY-100635	392.2 (224.1 to 686.2)	0.989

Example 3

Pharmacological Test

The forced swimming test proposed by Porsolt
et al. (Porsolt, R. D. et al.: Arch. Int. Pharmacodyn.,
5 229, 327-336, 1977) is widely used as to an
experimental animal model for predicting the
antidepressant activity in clinical settings. In this
experimental model, a test mouse is put in a cylinder
in which a suitable amount of water is contained, and
10 the antidepressant action of a test drug is detected by
measuring the immobility time, as the indication, shown
by the mouse. It was reported that the action of
shortening the immobility time is correlated with
clinically observed antidepressive action (Willner, P.:
15 Psychopharmacology, 83: 1-16, 1984). The crisis of
depression is closely concerned with lowering of
serotonin 5-HT1A receptor neurotransmission action, and
the present inventors have found the facts that

antidepressive action of antidepressants which affect to serotonin system can be detected more precisely using prolongation of the immobility time performed with WAY-100635, which is a selective serotonin 5-HT_{1A} receptor antagonist. The prolongation of the immobility time performed by WAY-100635 is defined as the indication. In this manner, the antidepressive action of test antidepressants was determined by taking the prolongation of immobility time performed by WAY-100635 in the forced swimming test as the indication.

In a cylinder (diameter: 9 cm, height 20 cm), water was poured therein up to the height of 9.5 cm, from the bottom, then a mouse of ICR strain is placed in the cylinder. After placing the mouse in the cylinder, an immobility time of 6 minutes is measured. During the test, the water temperature is maintained at 23 to 24°C. A test drug is orally administered to the mouse at 1 or 2 hours before placing the mouse in the water. WAY-100635 is administered subcutaneously to the mouse 30 minutes before placing the mouse in the water.

During this test, aripiprazole is used in combination together with citalopram, escitalopram, fluoxetine, venlafaxine or milnacipran. Following such combination administration, a decrease in the immobility time (the antidepressant activity) is observed in comparison with the case of single use of each one of aripiprazole, citalopram, escitalopram,

fluoxetine, venlafaxine or milnacipran, respectively.

Further, when aripiprazole is used in combination with citalopram, escitalopram, fluoxetine, venlafaxine or milnacipran, a decrease in the
5 immobility time (the antidepressant activity) is observed in comparison to administration of the available atypical antipsychotic drugs such as olanzapine, quetiapine, risperidone in combination with citalopram, fluoxetine, venlafaxine or milnacipran.

10 Example 4

Formulation Examples

Several non-limiting formulation examples of aripiprazole, dehydroaripiprazole and other metabolites with serotonin reuptake inhibitors are presented below.

15 Formulation Sample Example 1

	Aripiprazole Anhydride Crystals B	5 mg
	Fluoxetine	20 mg
	Starch	131 mg
	Magnesium stearate	4 mg
20	<u>Lactose</u>	<u>60 mg</u>
	Total	220 mg

According to a preparation method which is well-known to a person having an ordinary skill in the art, the tablet containing the above mentioned formula-
25 tion was prepared.

Formulation Sample Example 2

	Aripiprazole Anhydride Crystals B	5 mg
	Duloxetine	20 mg
	Starch	131 mg
5	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	220 mg

According to a common method, the tablet
containing the above mentioned formulation was
10 prepared.

Formulation Sample Example 3

	Aripiprazole Anhydride Crystals B	5 mg
	Venlafaxine	75 mg
	Starch	131 mg
15	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	275 mg

According to a common method, the tablet
containing the above mentioned formulation was
20 prepared.

Formulation Sample Example 4

	Aripiprazole Anhydride Crystals B	5 mg
	Milnacipran	50 mg
	Starch	131 mg
5	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	250 mg

According to a common method, the tablet
containing the above mentioned formulation was
10 prepared.

Formulation Sample Example 5

	Aripiprazole Anhydride Crystals B	5 mg
	Citalopram	20 mg
	Starch	131 mg
15	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	220 mg

According to a common method, the tablet
containing the above mentioned formulation was
20 prepared.

56

Formulation Sample Example 6

	Aripiprazole Anhydride Crystals B	5 mg
	Fluvoxamine	50 mg
	Starch	131 mg
5	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	250 mg

According to a common method, the tablet
containing the above mentioned formulation was
10 prepared.

Formulation Sample Example 7

	Aripiprazole Anhydride Crystals B	5 mg
	Paroxetine	20 mg
	Starch	131 mg
15	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	220 mg

According to a common method, the tablet
containing the above mentioned formulation was
20 prepared.

Formulation Sample Example 8

	Aripiprazole Anhydride Crystals B	5 mg
	Sertraline	50 mg
	Starch	131 mg
5	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	250 mg

According to a common method, the tablet
containing the above mentioned formulation was
10 prepared.

Formulation Sample Example 9

	Aripiprazole Anhydride Crystals B	5 mg
	Escitalopram	10 mg
	Starch	131 mg
15	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	210 mg

According to a common method, the tablet
containing the above mentioned formulation was
20 prepared.

Several non-limiting formulation examples of
dehydroaripiprazole and serotonin reuptake inhibitors
are presented below. It is to be understood that any
one of DM-1458, DM-1451, DM-1452, DM-1454 or DCPD, as
25 shown in Figure 8, could be substituted for
dehydroaripiprazole in these disclosed formulations.

Formulation Sample Example 10

	Dehydroaripiprazole	5 mg
	Fluoxetine	20 mg
	Starch	131 mg
5	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	220 mg

According to a preparation method which is well-known to a person having an ordinary skill in the art, the tablet containing the above mentioned formulation was prepared.

Formulation Sample Example 11

	Dehydroaripiprazole	5 mg
	Duloxetine	20 mg
15	Starch	131 mg
	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	220 mg

According to a common method, the tablet containing the above mentioned formulation was prepared.

Formulation Sample Example 12

	Dehydroaripiprazole	5 mg
	Venlafaxine	75 mg
	Starch	131 mg
5	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	275 mg

According to a common method, the tablet containing the above mentioned fomuration was prepared.

10 Formulation Sample Example 13

	Dehydroaripiprazole	5 mg
	Milnacipran	50 mg
	Starch	131 mg
	Magnesium stearate	4 mg
15	<u>Lactose</u>	<u>60 mg</u>
	Total	250 mg

According to a common method, the tablet containing the above mentioned formulation was prepared.

20 Formulation Sample Example 14

	Dehydroaripiprazole	5 mg
	Citalopram	20 mg
	Starch	131 mg
	Magnesium stearate	4 mg
25	<u>Lactose</u>	<u>60 mg</u>
	Total	220 mg

According to a common method, the tablet containing the above mentioned formulation was prepared.

Formulation Sample Example 15

5	Dehydroaripiprazole	5 mg
	Fluvoxamine	50 mg
	Starch	131 mg
	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
10	Total	250 mg

According to a common method, the tablet containing the above mentioned formulation was prepared.

Formulation Sample Example 16

15	Dehydroaripiprazole	5 mg
	Paroxetine	20 mg
	Starch	131 mg
	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
20	Total	220 mg

According to a common method, the tablet containing the above mentioned formulation was prepared.

61

Formulation Sample Example 17

	Dehydroaripiprazole	5 mg
	Sertraline	50 mg
	Starch	131 mg
5	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	250 mg

According to a common method, the tablet
containing the above mentioned formulation was
10 prepared.

Formulation Sample Example 18

	Dehydroaripiprazole	5 mg
	Escitalopram	10 mg
	Starch	131 mg
15	Magnesium stearate	4 mg
	<u>Lactose</u>	<u>60 mg</u>
	Total	210 mg

According to a common method, the tablet
containing the above mentioned formulation was
20 prepared.

Example 5

Method of Treatment of Patients Diagnosed with Major
Depressive Disorder Who Were Previously Non-responsive
or Partially Responsive to Anti-depressant Medication

25 Aripiprazole is evaluated as an augmentation
therapy in depressed patients with major depressive

disorder who were previously non-responsive or partially responsive to anti-depressant medication comprising serotonin reuptake inhibitors. These patients currently receive therapy through
5 administration of serotonin reuptake inhibitors.

Patients ranging in age from 18 to 65 years who have been diagnosed with major depressive disorder and are receiving therapy with a serotonin reuptake inhibitor are evaluated to ensure that they have a
10 baseline Hamilton score for depression (item 17) of 14 or higher. Only patients with such Hamilton scores receive treatment. These patients are interviewed to obtain a complete medical and psychiatric history. Aripiprazole is first administered at a dose of 10
15 mg/day and increased to 30 mg/day as needed in the opinion of the monitoring psychiatrist. Aripiprazole is administered to these patients at a dose of from 10 mg/day to 30 mg/day for a period of at least four weeks, and up to eight weeks for patients who respond
20 well to this treatment during the first four weeks.

An improvement in alleviation of symptoms of depression is observed in these patients following administration of aripiprazole as shown by results of testing performed during and after the duration of
25 aripiprazole administration. The Hamilton test for depression and other measures such as clinical global impression (CGI), abnormal involuntary movement scale (AIMS), Simpson Angus scale (SAS), and Barnes akathisia

scale (Barnes), commonly known to one of ordinary skill in the art, are administered to these patients.

Example 6

Method of Treatment of Patients with a New Diagnosis of
5 Major Depressive Disorder

A combination of aripiprazole and at least one serotonin reuptake inhibitor is evaluated as a therapy for depression in patients newly diagnosed with major depressive disorder. Patients ranging in age
10 from 18 to 65 years who are diagnosed with major depressive disorder are evaluated to ensure that they have a baseline Hamilton score for depression (item 17) of 14 or higher. Only patients with this Hamilton score receive treatment. These patients are
15 interviewed to obtain a complete medical and psychiatric history. Aripiprazole is first administered at a dose of 10 mg/day and increased to 30 mg/day as needed in the opinion of the monitoring psychiatrist. Aripiprazole is administered to these
20 patients at a dose of from 10 mg/day to 30 mg/day for a period of at least four weeks, and up to eight weeks for patients who respond well to this treatment during the first four weeks. The aripiprazole is administered together with at least one serotonin reuptake
25 inhibitor, wherein the serotonin reuptake inhibitor is fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine or sertraline. The

dosages to be used for these serotonin reuptake inhibitors are provided elsewhere in this patent application.

The aripiprazole can be administered in one dosage form, for example a tablet, and the serotonin reuptake inhibitor may be administered in a separate one dosage form, for example a tablet. The administration may occur at about the same time or at different times during the day.

Alternatively, a dosage form containing aripiprazole in combination with at least one serotonin reuptake inhibitor may be administered. Such combinations include without limitation the following: aripiprazole/fluoxetine, aripiprazole/duloxetine, aripiprazole/venlafaxine, aripiprazole/milnacipran, aripiprazole/citalopram, aripiprazole/fluvoxamine, aripiprazole/paroxetine, and aripiprazole/sertraline. A preferred embodiment comprises a combination of aripiprazole and citalopram.

An improvement in alleviation of symptoms of depression is observed in these patients following administration of aripiprazole and the one or more serotonin reuptake inhibitors as shown by results of testing performed during and after the duration of aripiprazole and serotonin reuptake inhibitor administration. The Hamilton test for depression and other measures such as CGI, AIMS, SAS, Simpson & Angus and Barnes, commonly known to one of ordinary skill in

the art, are administered to these patients. Results demonstrate an alleviation of the symptoms of depression.

Example 7

5 Method of Treatment of Patients Diagnosed with Major Depressive Disorder Who Were Previously Non-responsive or Partially Responsive to Anti-depressant Medication

Dehydroaripiprazole, an active metabolite of aripiprazole, is evaluated as an augmentation therapy
10 in depressed patients with major depressive disorder who were previously non-responsive or partially responsive to anti-depressant medication comprising serotonin reuptake inhibitors. These patients currently receive therapy through administration of
15 serotonin reuptake inhibitors.

Patients ranging in age from 18 to 65 years who have been diagnosed with major depressive disorder and are receiving therapy with a serotonin reuptake inhibitor are evaluated to ensure that they have a
20 baseline Hamilton score for depression (item 17) of 14 or higher. Only patients with such Hamilton scores receive treatment. These patients are interviewed to obtain a complete medical and psychiatric history. Dehydroaripiprazole is first administered at a dose of
25 10 mg/day and increased to 30 mg/day as needed in the opinion of the monitoring psychiatrist.

Dehydroaripiprazole is administered to these patients

at a dose of from 10 mg/day to 30 mg/day for a period of at least four weeks, and up to eight weeks for patients who respond well to this treatment during the first four weeks.

5 An improvement in alleviation of symptoms of depression is observed in these patients following administration of aripiprazole as shown by results of testing performed during and after the duration of aripiprazole administration. The Hamilton test for
10 depression and other measures such as clinical global impression (CGI), abnormal involuntary movement scale (AIMS), Simpson Angus scale (SAS), and Barnes akathisia rating scale (BARS), commonly known to one of ordinary skill in the art, are administered to these patients.

15 Example 8

Method of Treatment of Patients with a New Diagnosis of Major Depressive Disorder

 A combination of dehydroaripiprazole and at least one serotonin reuptake inhibitor is evaluated as
20 a therapy for depression in patients newly diagnosed with major depressive disorder. Patients ranging in age from 18 to 65 years who are diagnosed with major depressive disorder are evaluated to ensure that they have a baseline Hamilton score for depression (item 17)
25 of 14 or higher. Only patients with this Hamilton score receive treatment. These patients are interviewed to obtain a complete medical and

psychiatric history. Dehydroaripiprazole is first administered at a dose of 10 mg/day and increased to 30 mg/day as needed in the opinion of the monitoring psychiatrist. Dehydroaripiprazole is administered to these patients at a dose of from 10 mg/day to 30 mg/day for a period of at least four weeks, and up to eight weeks for patients who respond well to this treatment during the first four weeks. The dehydroaripiprazole is administered together with at least one serotonin reuptake inhibitor, wherein the serotonin reuptake inhibitor is fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine or sertraline.

The dehydroaripiprazole can be administered in one dosage form, for example a tablet, and the serotonin reuptake inhibitor may be administered in a separate one dosage form, for example a tablet. The administration may occur at about the same time or at different times during the day.

Alternatively, a dosage form containing dehydroaripiprazole in combination with at least one serotonin reuptake inhibitor may be administered. Such combinations include without limitation the following: dehydroaripiprazole/fluoxetine, dehydroaripiprazole/duloxetine, dehydroaripiprazole/venlafaxine, dehydroaripiprazole/milnacipran, dehydroaripiprazole/citalopram,

dehydroaripiprazole/fluvoxamine,
dehydroaripiprazole/paroxetine, and
dehydroaripiprazole/sertraline. A preferred embodiment
comprises a combination of dehydroaripiprazole and
5 citalopram.

An improvement in alleviation of symptoms of
depression is observed in these patients following
administration of dehydroaripiprazole and the one or
more serotonin reuptake inhibitors as shown by results
10 of testing performed during and after the duration of
dehydroaripiprazole and serotonin reuptake inhibitor
administration. The Hamilton test for depression and
other measures such as CGI, AIMS, SAS, Simpson & Angus
and Barnes, commonly known to one of ordinary skill in
15 the art, are administered to these patients. Results
demonstrate an alleviation of the symptoms of
depression.

All patents, patent applications, scientific
and medical publications mentioned herein are hereby
20 incorporated in their entirety. It should be
understood, of course, that the foregoing relates only
to preferred embodiments of the present invention and
that numerous modifications or alterations may be made
therein without departing from the spirit and the scope
25 of the invention as set forth in the appended claims.

Example 9

Pharmacological test

The tail suspension test (TST) was originally described by Steru et al. (1985).¹⁾ A mouse suspended by its tail shows periods of agitation and immobility. The antidepressant activity of a test drug can be detected as an index of shortening the immobility time. This test is widely used as to an experimental animal model for predicting the antidepressant activity of a test drug in clinical settings. An automated device for performing the TST was developed by the authors of the TST (1989).²⁾ We improved this device and developed our own device incorporating an electric balance, an A/D converter, a testing box (30×25×25 cm), and a personal computer. The mouse was suspended from a hook hanging from the ceiling in the testing box by adhesive tape applied 20 mm from the tip of the tail. The duration of immobility was measured by the computer for a period of 15 min following the start of suspension. The immobility time for a period of 10 min (5-15 min) was evaluated. The experiments were carried out in a sound-proof room.

Aripiprazole was suspended in 0.5% gum arabic-0.9% saline solution and citalopram was dissolved in 0.9% saline solution. Aripiprazole (3 mg/kg) and citalopram (3 mg/kg) were orally administered to mice 60 min before the start of suspension. In this test, the decrease in the

immobility time of the combination of aripiprazole with citalopram was statistically significant synergistic effect in comparison with the effects of aripiprazole- and citalopram-treated groups (Table 3).

5 References

- 1) Steru L. et al.: The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology 85, 367 (1985).
- 2) Steru L. and Porsolt R.D.: The automated
10 tail suspension test: A computerized device for evaluating psychotropic activity profiles. Jpn J Clin Pharmacol Ther 20, 77 (1989).

Table 3 Effects of aripiprazole and citalopram on duration of immobility in the tail suspension test in mice

Drug	Dose (mg/kg, p.o.)	Immobility time (sec, mean \pm SE)	% of shortening for immobility time
Vehicle	-	499.2 \pm 13.6	-
Aripiprazole (Aripi.)	3	486.4 \pm 12.3	3
Citalopram (Citalo.)	3	468.7 \pm 24.2	6
Aripi.+Citalo.	3+3	380.6 \pm 19.2**##\$	24

N=7-9, ** $p < 0.01$ vs. vehicle group (two-tailed t-test),
$p < 0.01$ vs. aripiprazole alone (two-tailed t-test),
\$ $p < 0.05$ vs. citalopram alone (two-tailed t-test).

The decrease in the immobility time of the combination of aripiprazole with citalopram was a statistically significant synergistic effect in comparison with the effects of aripiprazole- and citalopram-treated groups ($p < 0.05$, one-way ANOVA).

CLAIMS

1. A pharmaceutical composition comprising at least one carbostyryl derivative in combination with at least one serotonin reuptake inhibitor.
2. The composition of claim 1 wherein the carbostyryl derivative is a dopamine-serotonin system stabilizer.
3. The composition of claim 2 wherein the carbostyryl derivative is aripiprazole.
4. The composition of claim 2 wherein the carbostyryl derivative is a metabolite of aripiprazole.
5. The composition of claim 4 wherein the metabolite of aripiprazole is dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 or DCPD.
6. The composition of any one of claims 1 to 5, wherein at least one serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.
7. The composition of claim 6 wherein at least one serotonin reuptake inhibitor is citalopram.
8. The composition of claim 1, further comprising at least one pharmaceutically acceptable carrier.
9. The composition of any one of claims 1 to 7 being useful for treatment of mood disorders.
10. The composition of claim 9 wherein the mood

disorder is depression or major depressive disorder.

11. The composition of claim 9 wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.

12. The composition of any one of claims 1 to 7 being useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

13. Use of a pharmaceutical composition comprising at least one carbostyryl derivative in combination with at least one serotonin reuptake inhibitor, in the preparation of a medicament for treating disorders.

14. The use of claim 13 wherein the carbostyryl derivative is a dopamine-serotonin system stabilizer.

15. The use of claim 14 wherein the carbostyryl derivative is aripiprazole.

16. The use of claim 14 wherein the carbostyryl derivative is a metabolite of aripiprazole.

17. The use of claim 16 wherein the metabolite of aripiprazole is dehydroaripiprazole, DM-1458, DM-1451,

DM-1452, DM-1454 or DCPD.

18. The use of any one of claims 13 to 17, wherein at least one serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.
19. The use of claim 18 wherein at least one serotonin reuptake inhibitor is citalopram.
20. The use of claim 13 wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier.
21. The use of any one of claims 13 to 19 wherein the medicament is useful for treatment of mood disorders.
22. The use of claim 21 wherein the mood disorder is depression or major depressive disorder.
23. The use of claim 21 wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.
24. The use of any one of claims 13 to 19, wherein the medicament is useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with

depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

25. A method of treating disorders in a patient comprising administration of an effective amount of a pharmaceutical composition comprising at least one carbostyryl derivative in combination with at least one serotonin reuptake inhibitor.
26. The method of claim 25 wherein the carbostyryl derivative is a dopamine-serotonin system stabilizer.
27. The method of claim 26 wherein the carbostyryl derivative is aripiprazole.
28. The method of claim 26 wherein the carbostyryl derivative is a metabolite of aripiprazole.
29. The method of claim 28 wherein the metabolite of aripiprazole is dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 or DCPD.
30. The method of any one of claims 25 to 29, wherein at least one serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.
31. The method of claim 30 wherein at least one serotonin reuptake inhibitor is citalopram.
32. The method of claim 25, wherein the pharmaceutical composition further comprises at least

one pharmaceutically acceptable carrier.


33. The method of any one of claims 25 to 31 wherein the disorders are mood disorders.

34. The method of claim 33 wherein the mood disorder is depression or major depressive disorder.

35. The method of claim 33 wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.


36. The method of any one of claims 25 to 31, wherein the disorders are major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

1/8




2/8

FIG.2




3/8

FIG.3




4/8

FIG.4




5/8

FIG.5



6/8



7/8

FIG.7





FIG.8



INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 03/16724

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/496 A61K31/381 A61K31/343 A61K31/15 A61K31/4525
A61K31/135 A61P25/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, BIOSIS, CHEM ABS Data, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/156067 A1 (SVENSSON TORGNY ET AL) 24 October 2002 (2002-10-24) claims 1-10	1-3, 6, 8-15, 18, 20-27, 30, 32-36
Y	WO 02/060423 A (OTSUKA PHARMA CO LTD) 8 August 2002 (2002-08-08) cited in the application claims 1-5	1-36

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

6 May 2004

Date of mailing of the international search report

08/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 03/16724

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>LAWLER ET AL: "Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes" NEUROPSYCHOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 20, no. 6, June 1999 (1999-06), pages 612-627, XP002205416 ISSN: 0893-133X abstract</p>	<p>1-3, 6-15, 18-27, 30-36</p>
Y	<p>BURRIS K D ET AL: "ARIPIPRAZOLE, A NOVEL ANTIPSYCHOTIC, IS A HIGH-AFFINITY PARTIAL AGONIST AT HUMAN DOPAMINE D2 RECEPTORS" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 302, no. 1, July 2002 (2002-07), pages 381-389, XP001087706 ISSN: 0022-3565 abstract</p>	<p>1-3, 6-15, 18-27, 30-36</p>
Y	<p>GOODMAN ET AL: "THE PHARMACOLOGICAL BASIS OF THERAPEUTICS" , PHARMACOLOGICAL BASIS OF THERAPEUTICS, GOODMAN GILMAN'S PHARMACOLOGICAL BASIS OF THERAPEUTICS, NEW YORK, PERGAMON PRESS, US, VOL. ED. 10, PAGE(S) 451, 468 , 2001 XP002279121 page 451, column 2, paragraph 2 page 468, column 1, paragraph 4</p>	<p>1-36</p>
P,X	<p>PRESKORN S H: "Relating clinical trials to psychiatric practice: Part I: The case of a 13-year old on aripiprazole and fluoxetine" JOURNAL OF PSYCHIATRIC PRACTICE 2003 UNITED STATES, vol. 9, no. 4, July 2003 (2003-07), pages 307-313, XP008029355 ISSN: 1527-4160 page 307, column 2, paragraph 2 page 308, column 2, paragraph 3</p>	<p>1-3,6, 8-15,18, 20-27, 30,32-36</p>
P,X	<p>GREEN B: "FOCUS ON ARIPIPRAZOLE" CURRENT MEDICAL RESEARCH AND OPINION, HANTS, GB, vol. 20, no. 2, 12 December 2003 (2003-12-12), pages 207-213, XP008029340 page 211, column 2, paragraph 12</p>	<p>1-3,6, 8-15,18, 20-27, 30,32-36</p>
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/JP 03/16724

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 2004/010932 A (MIGALY PETER) 5 February 2004 (2004-02-05)</p> <p>claims 19,23,31</p>	<p>1-3,6, 8-15,18, 20-27, 30,32-36</p>

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-36

The terms "carbostyryl derivative" and "metabolite of aripiprazole" used in claims 1, 2, 4, 6-14, 16, 18-26, 28, 30-36 are vague and unclear and leave the reader in doubt as to the meaning of the technical features (i.e. the compounds) to which they refer, thereby rendering the definition of the subject-matter of said claims unclear (Article 6 PCT). Independent of the above, the Applicant has not provided any test to demonstrate whether a compound is a metabolite of aripiprazole or not. There is therefore insufficient disclosure (Art. 5 PCT) to allow the skilled man to determine which compounds fall within the definition.

Claims 1-36 encompass a genus of compounds defined only by their function ("dopamine-serotonin system stabilizer" and "serotonin reuptake inhibitor"), wherein the relationship between the structural features of the members of the genus and said function have not been defined. In the absence of such a relationship either disclosed in the as-filed application or which would have been recognized based upon information readily available to one skilled in the art, the skilled artisan would not know how to make and use compounds that lack structural definition.

Present claims 9, 11, 13-21, 23, 25-33 and 35 relate to an extremely large number of disease states. The therapeutic application is defined as "mood disorders" or even "disorders" which does not allow any practical application in the form of a defined, real treatment of a pathological condition. It is noted that any disease may represent a disorder. A lack of clarity (and/or conciseness) within the meaning of Art. 6 PCT therefore arises.

Independent of the above, the Applicant has not provided any test to demonstrate whether a disease is a mood disorder or not. There is therefore insufficient disclosure (Art. 5 PCT) to allow the skilled man to determine which diseases fall within the definition.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to compositions comprising aripiprazole, dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 or N-(2,3-Dichlorophenyl)piperazine in combination with fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram in relation to their use in the treatment of depression or major depressive disorder.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP 03/16724

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 25-36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-36
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 03/16724

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2002156067	A1	24-10-2002	CA 2431041 A1	11-07-2002
			EP 1353675 A2	22-10-2003
			WO 02053140 A2	11-07-2002
WO 02060423	A	08-08-2002	BR 0206237 A	23-12-2003
			CA 2429496 A1	08-08-2002
			CN 1484524 T	24-03-2004
			EP 1355639 A2	29-10-2003
			WO 02060423 A2	08-08-2002
WO 2004010932	A	05-02-2004	WO 2004010932 A2	05-02-2004